FDA expands J&J's psoriasis drug for inflammatory bowel disease

The U.S. Food and Drug Administration has allowed the expanded use of Johnson & Johnson's (JNJ.N) drug, Tremfya, to treat adults with a type of chronic inflammatory bowel disease, the company said on Wednesday.